Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
methylprednisolone
Overview
What is Medrol?
MEDROL Tablets contain methylprednisolone which is a glucocorticoid. Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic, which are readily absorbed from the gastrointestinal tract. Methylprednisolone occurs as a white to practically white, odorless, crystalline powder. It is sparingly soluble in alcohol, in dioxane, and in methanol, slightly soluble in acetone, and in chloroform, and very slightly soluble in ether. It is practically insoluble in water.
The chemical name for methylprednisolone is pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6α,11β)-and the molecular weight is 374.48. The structural formula is represented below:
Each MEDROL Tablet for oral administration contains 2 mg, 4 mg, 8 mg, 16 mg or 32 mg of methylprednisolone.
Inactive ingredients:
What does Medrol look like?
What are the available doses of Medrol?
Sorry No records found.
What should I talk to my health care provider before I take Medrol?
Sorry No records found
How should I use Medrol?
MEDROL Tablets are indicated in the following conditions:
The initial dosage of MEDROL Tablets may vary from 4 mg to 48 mg of methylprednisolone per day depending on the specific disease entity being treated. In situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time there is a lack of satisfactory clinical response, MEDROL should be discontinued and the patient transferred to other appropriate therapy.
IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT.
What interacts with Medrol?
Systemic fungal infections and known hypersensitivity to components.
What are the warnings of Medrol?
In late pregnancy, as with other NSAIDs, ibuprofen tablets should be avoided because it may cause premature closure of the ductus arteriosus.
In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated.
Corticosteroids may mask some signs of infection, and new infections may appear during their use. Infections with any pathogen including viral, bacterial, fungal, protozoan or helminthic infections, in any location of the body, may be associated with the use of corticosteroids alone or in combination with other immunosuppressive agents that affect cellular immunity, humoral immunity, or neutrophil function.
These infections may be mild, but can be severe and at times fatal. With increasing doses of corticosteroids, the rate of occurrence of infectious complications increases.
There may be decreased resistance and inability to localize infection when corticosteroids are used.
Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses.
Usage in pregnancy
Since adequate human reproduction studies have not been done with corticosteroids, the use of these drugs in pregnancy, nursing mothers or women of child-bearing potential requires that the possible benefits of the drug be weighed against the potential hazards to the mother and embryo or fetus. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy, should be carefully observed for signs of hypoadrenalism.
Array
Average and large doses of hydrocortisone or cortisone can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion.
Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids. Killed or inactivated vaccines may be administered to patients receiving immunosuppressive doses of corticosteroids; however, the response to such vaccines may be diminished. Indicated immunization procedures may be undertaken in patients receiving nonimmunosuppressive doses of corticosteroids.
The use of MEDROL Tablets in active tuberculosis should be restricted to those cases of fulminating or disseminated tuberculosis in which the corticosteroid is used for the management of the disease in conjunction with an appropriate antituberculous regimen.
If corticosteroids are indicated in patients with latent tuberculosis or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur. During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis.
Persons who are on drugs which suppress the immune system are more susceptible to infections than healthy individuals. Chicken pox and measles, for example, can have a more serious or even fatal course in non-immune children or adults on corticosteroids. In such children or adults who have not had these diseases particular care should be taken to avoid exposure. How the dose, route and duration of corticosteroid administration affects the risk of developing a disseminated infection is not known. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If exposed, to chicken pox, prophylaxis with varicella zoster immune globulin (VZIG) may be indicated. If exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. (See the respective package inserts for complete VZIG and IG prescribing information.) If chicken pox develops, treatment with antiviral agents may be considered. Similarly, corticosteroids should be used with great care in patients with known or suspected Strongyloides (threadworm) infestation. In such patients, corticosteroid-induced immunosuppression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.
What are the precautions of Medrol?
General Precautions
Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently.
There is an enhanced effect of corticosteroids on patients with hypothyroidism and in those with cirrhosis.
Corticosteroids should be used cautiously in patients with ocular herpes simplex because of possible corneal perforation.
The lowest possible dose of corticosteroid should be used to control the condition under treatment, and when reduction in dosage is possible, the reduction should be gradual.
Psychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression, to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids.
Caution is required in patients with systemic sclerosis because an increased incidence of scleroderma renal crisis has been observed with corticosteroids, including methylprednisolone.
Steroids should be used with caution in nonspecific ulcerative colitis, if there is a probability of impending perforation, abscess or other pyogenic infection; diverticulitis; fresh intestinal anastomoses; active or latent peptic ulcer; renal insufficiency; hypertension; osteoporosis; and myasthenia gravis.
Growth and development of infants and children on prolonged corticosteroid therapy should be carefully observed.
Kaposi's sarcoma has been reported to occur in patients receiving corticosteroid therapy. Discontinuation of corticosteroids may result in clinical remission.
Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of multiple sclerosis, they do not show that corticosteroids affect the ultimate outcome or natural history of the disease. The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect. (See
.)
Since complications of treatment with glucocorticoids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used.
Drug Interactions
The pharmacokinetic interactions listed below are potentially clinically important. Mutual inhibition of metabolism occurs with concurrent use of cyclosporin and methylprednisolone; therefore, it is possible that adverse events associated with the individual use of either drug may be more apt to occur. Convulsions have been reported with concurrent use of methylprednisolone and cyclosporin. Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of methylprednisolone and may require increases in methylprednisolone dose to achieve the desired response. Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. Therefore, the dose of methylprednisolone should be titrated to avoid steroid toxicity.
Methylprednisolone may increase the clearance of chronic high dose aspirin. This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn. Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia.
The effect of methylprednisolone on oral anticoagulants is variable. There are reports of enhanced as well as diminished effects of anticoagulant when given concurrently with corticosteroids. Therefore, coagulation indices should be monitored to maintain the desired anticoagulant effect.
Information for the Patient
Persons who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chickenpox or measles. Patients should also be advised that if they are exposed, medical advice should be sought without delay.
What are the side effects of Medrol?
Fluid and Electrolyte Disturbances
Musculoskeletal
Gastrointestinal
Increases in alanine transaminase (ALT, SGPT), aspartate transaminase (AST, SGOT), and alkaline phosphatase have been observed following corticosteroid treatment. These changes are usually small, not associated with any clinical syndrome and are reversible upon discontinuation.
Dermatologic
Neurological
Endocrine
Ophthalmic
Metabolic
The following additional reactions have been reported following oral as well as parenteral therapy: Urticaria and other allergic, anaphylactic or hypersensitivity reactions.
What should I look out for while using Medrol?
Systemic fungal infections and known hypersensitivity to components.
In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated.
Corticosteroids may mask some signs of infection, and new infections may appear during their use. Infections with any pathogen including viral, bacterial, fungal, protozoan or helminthic infections, in any location of the body, may be associated with the use of corticosteroids alone or in combination with other immunosuppressive agents that affect cellular immunity, humoral immunity, or neutrophil function.
These infections may be mild, but can be severe and at times fatal. With increasing doses of corticosteroids, the rate of occurrence of infectious complications increases.
There may be decreased resistance and inability to localize infection when corticosteroids are used.
Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses.
What might happen if I take too much Medrol?
Sorry No Records found
How should I store and handle Medrol?
Unopened vials of gemcitabine for injection, USP are stable until the expiration date indicated on the package when stored at controlled room temperature 20° to 25°C (68° to 77°F) and that allows for excursions between 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature] [].MEDROL Tablets are available in the following strengths and package sizes:2 mg Bottles of 100 NDC 0009-0049-022 mg Bottles of 100 NDC 0009-0020-014 mg Bottles of 100 NDC 0009-0056-02 Bottles of 500 NDC 0009-0056-03 Unit dose packages of 100 NDC 0009-0056-05 DOSEPAK Unit of Use (21 tablets) NDC 0009-0056-04 8 mg Bottles of 25 NDC 0009-0022-0116 mg Bottles of 50 NDC 0009-0073-0132 mg Bottles of 25 NDC 0009-0176-01MEDROL Tablets are available in the following strengths and package sizes:2 mg Bottles of 100 NDC 0009-0049-022 mg Bottles of 100 NDC 0009-0020-014 mg Bottles of 100 NDC 0009-0056-02 Bottles of 500 NDC 0009-0056-03 Unit dose packages of 100 NDC 0009-0056-05 DOSEPAK Unit of Use (21 tablets) NDC 0009-0056-04 8 mg Bottles of 25 NDC 0009-0022-0116 mg Bottles of 50 NDC 0009-0073-0132 mg Bottles of 25 NDC 0009-0176-01MEDROL Tablets are available in the following strengths and package sizes:2 mg Bottles of 100 NDC 0009-0049-022 mg Bottles of 100 NDC 0009-0020-014 mg Bottles of 100 NDC 0009-0056-02 Bottles of 500 NDC 0009-0056-03 Unit dose packages of 100 NDC 0009-0056-05 DOSEPAK Unit of Use (21 tablets) NDC 0009-0056-04 8 mg Bottles of 25 NDC 0009-0022-0116 mg Bottles of 50 NDC 0009-0073-0132 mg Bottles of 25 NDC 0009-0176-01MEDROL Tablets are available in the following strengths and package sizes:2 mg Bottles of 100 NDC 0009-0049-022 mg Bottles of 100 NDC 0009-0020-014 mg Bottles of 100 NDC 0009-0056-02 Bottles of 500 NDC 0009-0056-03 Unit dose packages of 100 NDC 0009-0056-05 DOSEPAK Unit of Use (21 tablets) NDC 0009-0056-04 8 mg Bottles of 25 NDC 0009-0022-0116 mg Bottles of 50 NDC 0009-0073-0132 mg Bottles of 25 NDC 0009-0176-01MEDROL Tablets are available in the following strengths and package sizes:2 mg Bottles of 100 NDC 0009-0049-022 mg Bottles of 100 NDC 0009-0020-014 mg Bottles of 100 NDC 0009-0056-02 Bottles of 500 NDC 0009-0056-03 Unit dose packages of 100 NDC 0009-0056-05 DOSEPAK Unit of Use (21 tablets) NDC 0009-0056-04 8 mg Bottles of 25 NDC 0009-0022-0116 mg Bottles of 50 NDC 0009-0073-0132 mg Bottles of 25 NDC 0009-0176-01MEDROL Tablets are available in the following strengths and package sizes:2 mg Bottles of 100 NDC 0009-0049-022 mg Bottles of 100 NDC 0009-0020-014 mg Bottles of 100 NDC 0009-0056-02 Bottles of 500 NDC 0009-0056-03 Unit dose packages of 100 NDC 0009-0056-05 DOSEPAK Unit of Use (21 tablets) NDC 0009-0056-04 8 mg Bottles of 25 NDC 0009-0022-0116 mg Bottles of 50 NDC 0009-0073-0132 mg Bottles of 25 NDC 0009-0176-01MEDROL Tablets are available in the following strengths and package sizes:2 mg Bottles of 100 NDC 0009-0049-022 mg Bottles of 100 NDC 0009-0020-014 mg Bottles of 100 NDC 0009-0056-02 Bottles of 500 NDC 0009-0056-03 Unit dose packages of 100 NDC 0009-0056-05 DOSEPAK Unit of Use (21 tablets) NDC 0009-0056-04 8 mg Bottles of 25 NDC 0009-0022-0116 mg Bottles of 50 NDC 0009-0073-0132 mg Bottles of 25 NDC 0009-0176-01MEDROL Tablets are available in the following strengths and package sizes:2 mg Bottles of 100 NDC 0009-0049-022 mg Bottles of 100 NDC 0009-0020-014 mg Bottles of 100 NDC 0009-0056-02 Bottles of 500 NDC 0009-0056-03 Unit dose packages of 100 NDC 0009-0056-05 DOSEPAK Unit of Use (21 tablets) NDC 0009-0056-04 8 mg Bottles of 25 NDC 0009-0022-0116 mg Bottles of 50 NDC 0009-0073-0132 mg Bottles of 25 NDC 0009-0176-01MEDROL Tablets are available in the following strengths and package sizes:2 mg Bottles of 100 NDC 0009-0049-022 mg Bottles of 100 NDC 0009-0020-014 mg Bottles of 100 NDC 0009-0056-02 Bottles of 500 NDC 0009-0056-03 Unit dose packages of 100 NDC 0009-0056-05 DOSEPAK Unit of Use (21 tablets) NDC 0009-0056-04 8 mg Bottles of 25 NDC 0009-0022-0116 mg Bottles of 50 NDC 0009-0073-0132 mg Bottles of 25 NDC 0009-0176-01MEDROL Tablets are available in the following strengths and package sizes:2 mg Bottles of 100 NDC 0009-0049-022 mg Bottles of 100 NDC 0009-0020-014 mg Bottles of 100 NDC 0009-0056-02 Bottles of 500 NDC 0009-0056-03 Unit dose packages of 100 NDC 0009-0056-05 DOSEPAK Unit of Use (21 tablets) NDC 0009-0056-04 8 mg Bottles of 25 NDC 0009-0022-0116 mg Bottles of 50 NDC 0009-0073-0132 mg Bottles of 25 NDC 0009-0176-01MEDROL Tablets are available in the following strengths and package sizes:2 mg Bottles of 100 NDC 0009-0049-022 mg Bottles of 100 NDC 0009-0020-014 mg Bottles of 100 NDC 0009-0056-02 Bottles of 500 NDC 0009-0056-03 Unit dose packages of 100 NDC 0009-0056-05 DOSEPAK Unit of Use (21 tablets) NDC 0009-0056-04 8 mg Bottles of 25 NDC 0009-0022-0116 mg Bottles of 50 NDC 0009-0073-0132 mg Bottles of 25 NDC 0009-0176-01MEDROL Tablets are available in the following strengths and package sizes:2 mg Bottles of 100 NDC 0009-0049-022 mg Bottles of 100 NDC 0009-0020-014 mg Bottles of 100 NDC 0009-0056-02 Bottles of 500 NDC 0009-0056-03 Unit dose packages of 100 NDC 0009-0056-05 DOSEPAK Unit of Use (21 tablets) NDC 0009-0056-04 8 mg Bottles of 25 NDC 0009-0022-0116 mg Bottles of 50 NDC 0009-0073-0132 mg Bottles of 25 NDC 0009-0176-01MEDROL Tablets are available in the following strengths and package sizes:2 mg Bottles of 100 NDC 0009-0049-022 mg Bottles of 100 NDC 0009-0020-014 mg Bottles of 100 NDC 0009-0056-02 Bottles of 500 NDC 0009-0056-03 Unit dose packages of 100 NDC 0009-0056-05 DOSEPAK Unit of Use (21 tablets) NDC 0009-0056-04 8 mg Bottles of 25 NDC 0009-0022-0116 mg Bottles of 50 NDC 0009-0073-0132 mg Bottles of 25 NDC 0009-0176-01MEDROL Tablets are available in the following strengths and package sizes:2 mg Bottles of 100 NDC 0009-0049-022 mg Bottles of 100 NDC 0009-0020-014 mg Bottles of 100 NDC 0009-0056-02 Bottles of 500 NDC 0009-0056-03 Unit dose packages of 100 NDC 0009-0056-05 DOSEPAK Unit of Use (21 tablets) NDC 0009-0056-04 8 mg Bottles of 25 NDC 0009-0022-0116 mg Bottles of 50 NDC 0009-0073-0132 mg Bottles of 25 NDC 0009-0176-01MEDROL Tablets are available in the following strengths and package sizes:2 mg Bottles of 100 NDC 0009-0049-022 mg Bottles of 100 NDC 0009-0020-014 mg Bottles of 100 NDC 0009-0056-02 Bottles of 500 NDC 0009-0056-03 Unit dose packages of 100 NDC 0009-0056-05 DOSEPAK Unit of Use (21 tablets) NDC 0009-0056-04 8 mg Bottles of 25 NDC 0009-0022-0116 mg Bottles of 50 NDC 0009-0073-0132 mg Bottles of 25 NDC 0009-0176-01MEDROL Tablets are available in the following strengths and package sizes:2 mg Bottles of 100 NDC 0009-0049-022 mg Bottles of 100 NDC 0009-0020-014 mg Bottles of 100 NDC 0009-0056-02 Bottles of 500 NDC 0009-0056-03 Unit dose packages of 100 NDC 0009-0056-05 DOSEPAK Unit of Use (21 tablets) NDC 0009-0056-04 8 mg Bottles of 25 NDC 0009-0022-0116 mg Bottles of 50 NDC 0009-0073-0132 mg Bottles of 25 NDC 0009-0176-01
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Non-Clinical Toxicology
Systemic fungal infections and known hypersensitivity to components.In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated.
Corticosteroids may mask some signs of infection, and new infections may appear during their use. Infections with any pathogen including viral, bacterial, fungal, protozoan or helminthic infections, in any location of the body, may be associated with the use of corticosteroids alone or in combination with other immunosuppressive agents that affect cellular immunity, humoral immunity, or neutrophil function.
These infections may be mild, but can be severe and at times fatal. With increasing doses of corticosteroids, the rate of occurrence of infectious complications increases. There may be decreased resistance and inability to localize infection when corticosteroids are used.
Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses.
The pharmacokinetic interactions listed below are potentially clinically important. Mutual inhibition of metabolism occurs with concurrent use of cyclosporin and methylprednisolone; therefore, it is possible that adverse events associated with the individual use of either drug may be more apt to occur. Convulsions have been reported with concurrent use of methylprednisolone and cyclosporin. Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of methylprednisolone and may require increases in methylprednisolone dose to achieve the desired response. Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. Therefore, the dose of methylprednisolone should be titrated to avoid steroid toxicity.
Methylprednisolone may increase the clearance of chronic high dose aspirin. This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn. Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia.
The effect of methylprednisolone on oral anticoagulants is variable. There are reports of enhanced as well as diminished effects of anticoagulant when given concurrently with corticosteroids. Therefore, coagulation indices should be monitored to maintain the desired anticoagulant effect.
Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently.
There is an enhanced effect of corticosteroids on patients with hypothyroidism and in those with cirrhosis.
Corticosteroids should be used cautiously in patients with ocular herpes simplex because of possible corneal perforation.
The lowest possible dose of corticosteroid should be used to control the condition under treatment, and when reduction in dosage is possible, the reduction should be gradual.
Psychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression, to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids.
Caution is required in patients with systemic sclerosis because an increased incidence of scleroderma renal crisis has been observed with corticosteroids, including methylprednisolone.
Steroids should be used with caution in nonspecific ulcerative colitis, if there is a probability of impending perforation, abscess or other pyogenic infection; diverticulitis; fresh intestinal anastomoses; active or latent peptic ulcer; renal insufficiency; hypertension; osteoporosis; and myasthenia gravis.
Growth and development of infants and children on prolonged corticosteroid therapy should be carefully observed.
Kaposi's sarcoma has been reported to occur in patients receiving corticosteroid therapy. Discontinuation of corticosteroids may result in clinical remission.
Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of multiple sclerosis, they do not show that corticosteroids affect the ultimate outcome or natural history of the disease. The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect. (See .)
Since complications of treatment with glucocorticoids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used.
Fluid and Electrolyte Disturbances
Musculoskeletal
Gastrointestinal
Increases in alanine transaminase (ALT, SGPT), aspartate transaminase (AST, SGOT), and alkaline phosphatase have been observed following corticosteroid treatment. These changes are usually small, not associated with any clinical syndrome and are reversible upon discontinuation.
Dermatologic
Neurological
Endocrine
Ophthalmic
Metabolic
The following additional reactions have been reported following oral as well as parenteral therapy: Urticaria and other allergic, anaphylactic or hypersensitivity reactions.
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
514Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).